Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Tirzepatide (commonly known as Mounjaro or Zepbound) a newer option that targets both GLP-1 and GIP receptors, often leading to even greater weight loss compared to semaglutide
After drawing your dose, hold the syringe needle-up, tap the barrel to move bubbles to the top, then push the plunger gently until the air is expelled and a tiny drop of liquid appears at the needle tip
Over a 52-week study, 75% to 90% of people taking Mounjaro (with or without diabetes medications) reached an A1C of less than 7%, with an average starting A1C of 7.9% to 8.6%, showing a significant difference within a year
While such compounds have been described, none have yet been considered credible pharmacological candidates (253, 254) due to a combination of factors, including insufficient potency, lack of specificity of binding to the GLP-1R and suboptimal half-life
Oral semaglutide is different because the manufacturing process involves an absorption enhancer called SNAC (salcaprozate sodium)
